Capstan Therapeutics - About the company
Capstan Therapeutics is an acquired company based in San Diego (United States), founded in 2021 by Christian Homsy. It operates as a Developer of cell therapies for a broad range of diseases. Capstan Therapeutics has raised $340M in funding from investors like Pfizer, RA Capital Management and Novartis Venture Fund. The company has 3192 active competitors, including 1098 funded and 761 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications.
Company Details
Developer of cell therapies for a broad range of diseases. The company's technology comprises targeted lipid nanoparticles (tLNPs), CAR-based immunotherapy, and nucleic acid drug delivery to develop treatment options for patients for oncology, fibrosis, inflammation-related diseases, and monogenic blood disorders.
- Website
- capstantx.com
- Social
- Email ID
- *****@capstantx.com
Key Metrics
Founded Year
2021
Location
San Diego, United States
Stage
Acquired
Total Funding
$340M in 3 rounds
Latest Funding Round
Ranked
170th among 3192 active competitors
Employee Count
35 as on Mar 31, 2026
Similar Companies
Exit Details
Acquired by AbbVie (Jul 01, 2025)
Capstan Therapeutics's acquisition details
Click here to take a look at Capstan Therapeutics's acquisition in detail
Sign up to download Capstan Therapeutics' company profile
Capstan Therapeutics's funding and investors
Capstan Therapeutics has raised a total funding of $340M over 3 rounds. Its first funding round was on Nov 24, 2021. Its latest funding round was a Series B round on Mar 05, 2024 for $*****. 15 investors participated in its latest round. Capstan Therapeutics has 15 institutional investors.
Here is the list of recent funding rounds of Capstan Therapeutics:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 05, 2024 | 4013946 | Series B | 3335475 | 7023431 | 9216290 | 5938197 |
Jun 14, 2022 | 1857134 | Series A | 3089494 | 6659849 | 6303395 | |
Nov 24, 2021 | 4415062 | Seed | 4471621 | 3265685 |
Access funding benchmarks and valuations. Sign up today!View details of Capstan Therapeutics's funding rounds and investors
Capstan Therapeutics' founders and board of directors
Founder? Claim ProfileThe founders of Capstan Therapeutics is Christian Homsy. Laura Shawver is the CEO of Capstan Therapeutics.
Here are the details of Capstan Therapeutics' key team members:
- Christian Homsy: Co-Founder of Capstan Therapeutics.
- Laura Shawver: CEO of Capstan Therapeutics. Contact Info: 1 email address
View details of Capstan Therapeutics's Founder profiles and Board Members
Capstan Therapeutics' employee count trend
Capstan Therapeutics has 35 employees as of Mar 26. Here is Capstan Therapeutics's employee count trend over the years:
Uncover Capstan Therapeutics' growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Capstan Therapeutics's Competitors and alternates
Top competitors of Capstan Therapeutics include Jazz Pharmaceuticals, Kite Pharma and Advanced Accelerator Applications. Here is the list of Top 10 competitors of Capstan Therapeutics, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd | Kite Pharma 2009, Los Angeles (United States), Acquired | Developer of cancer immunotherapy products using genetic engineering | $97.7M | 79/100 | |
3rd |  Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | 78/100 | |
4th |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
5th | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
6th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
7th | Immunocore 2008, Abingdon (United Kingdom), Public | Developer of drugs based on T-Cell receptor technology for the treatment of cancer | $601M | 74/100 | |
8th | FibroGen 1993, San Francisco (United States), Public | Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | $215M | 72/100 | |
9th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
10th |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 72/100 | |
170th |  Capstan Therapeutics 2021, San Diego (United States), Acquired | Developer of cell therapies for a broad range of diseases | $340M | 60/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Capstan Therapeutics's competitors? Click here to see the top ones
Capstan Therapeutics's Investments and acquisitions
Capstan Therapeutics has made no investments or acquisitions yet.
Reports related to Capstan Therapeutics
Here is the latest report on Capstan Therapeutics's sector:
News related to Capstan Therapeutics
Filter this listMedia has covered Capstan Therapeutics for a total of 4 events in the last 1 year, 1 of them has been about company updates.
•
AbbVie Completes Acquisition of Capstan TherapeuticsFinancial Times•Aug 19, 2025•Capstan Therapeutics, AbbVie
•
FORT Robotics Secures $18.9 Million in Series B, Totaling $60.5 Million for Robotics Safety InnovationRoboticsTomorrow•Aug 07, 2025•Fort Robotics, John Deere, Tiger Global Management, Neman Ventures and 17 others
•
•
Enabling the Body To Engineer Its Own CAR T CellsTechnology Networks•Jun 20, 2025•Capstan Therapeutics
•
•
•
Forbion participates in US financing roundsEuropean Biotechnology•Apr 03, 2024•Engrail Therapeutics, Capstan Therapeutics, Forbion, RA Capital Management and 13 others
•
Capstan secures $175m Series B funds for CAR-T therapyPharmaceutical Technology•Mar 21, 2024•Capstan Therapeutics, RA Capital Management, Forbion, Johnson & Johnson Innovation and 13 others
•
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Capstan Therapeutics
Explore our recently published companies
- Lumozion - Delhi based, 2024 founded, Unfunded company
- Made by Porter - Los Angeles based, 2004 founded, Unfunded company
- Grafikburo Sudheide - Hermannsburg based, 2014 founded, Unfunded company
- BOT Rohstoffe - Wiehl based, 2001 founded, Public company
- Wayca - Gurugram based, 2025 founded, Unfunded company
- Full Support Healthcare - Wellingborough based, 2004 founded, Unfunded company
